Novo Nordisk says Wegovy starter-dose supply limits will last into 2024

Novo Nordisk said on Aug. 10, 2023, that supply limits on the lower, starting doses of its weight-loss drug Wegovy will continue into 2024, months later than the company had previously signaled ^[1]. The restriction lands hardest on people who have not yet begun treatment ^[1].

Wegovy is the brand name for semaglutide, the same active molecule sold as Ozempic and Rybelsus for other uses.

The new timeline extends a supply problem that had already been running through 2023 and pushes the expected return to normal availability past the point Novo had earlier indicated. Novo has not disclosed a specific month in 2024 when it expects the limits to end, or what changed in its forecast ^[1].

What is affected. The restriction described applies to the lower, starter doses of Wegovy rather than to every dose of the drug ^[1]. Treatment with Wegovy begins at a low dose and steps up over weeks, so a patient who cannot fill a starting prescription generally cannot begin therapy at all.

What is not known. Not reported: which specific starter strengths are affected, how many patients are waiting, whether the limits apply across all pharmacies and regions, or what manufacturing steps Novo expects to relieve the constraint ^[1]. The company has not said when it will next update its guidance ^[1].

Why it matters for patients

People already taking Wegovy at a maintenance dose are not the group described as affected by the new limits ^[1]. The practical squeeze falls on new patients — those whose prescribers have written a first prescription and who are trying to start.

How long an individual patient should expect to wait, whether any particular pharmacy is more likely to have starter doses in stock, and whether insurance plans would cover a temporary switch to another medication have not been reported ^[1].

Because the drug is taken at increasing doses over time rather than at a single fixed dose, a patient who cannot start also cannot move up. No alternative starting pathway from Novo has been reported ^[1].

No change to Wegovy's approved uses or to how it is dosed has been reported ^[1]. Decisions about waiting, switching to another product or pausing a treatment plan depend on a patient's own circumstances and prescriber, and the details needed to compare those options were not part of what Novo disclosed ^[1].

What happens next

The stated milestone is the end of the supply limits at some point in 2024 ^[1]. No month, quarter or trigger for that change has been disclosed ^[1]. Novo has not said whether it will issue further updates before then ^[1].